Zura Bio Ltd Ordinary Shares - Class A ZURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zura Bio to Present at Three Upcoming Investor Conferences in September
-
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
-
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
-
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
-
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
Trading Information
- Previous Close Price
- $3.97
- Day Range
- $3.91–4.17
- 52-Week Range
- $2.00–7.22
- Bid/Ask
- $3.73 / $5.00
- Market Cap
- $259.56 Mil
- Volume/Avg
- 393,346 / 478,659
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 15
- Website
- https://www.zurabio.com
Comparables
Valuation
|
Metric
|
ZURA
|
02171
|
06855
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.66 | 1.56 | 175.16 |
Price/Sales | — | 347.20 | 12.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ZURA
|
02171
|
06855
|
|---|---|---|---|
Quick Ratio | 12.50 | 9.12 | 1.32 |
Current Ratio | 12.57 | 9.47 | 1.44 |
Interest Coverage | — | −159.86 | −9.05 |
Quick Ratio
ZURA
02171
06855
Profitability
|
Metric
|
ZURA
|
02171
|
06855
|
|---|---|---|---|
Return on Assets (Normalized) | −20.26% | −29.55% | −32.67% |
Return on Equity (Normalized) | −29.67% | −39.55% | −254.45% |
Return on Invested Capital (Normalized) | −30.68% | −38.18% | −39.49% |
Return on Assets
ZURA
02171
06855
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mtnqfrhx | Hcm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wgthgtqd | Zbmft | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kwxvxwxq | Yqsxc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ttbdhtxwq | Pdswh | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Tqtvbswf | Nbjz | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kdlbmcqbv | Gtbtn | $28.1 Bil | |||
| Moderna Inc
MRNA
| Rcntdmmzr | Bwwp | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qfrsrwtp | Llk | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wcpswvmdz | Hsfqpjf | $13.4 Bil | |||
| Incyte Corp
INCY
| Rvqlkmh | Stqzzp | $12.7 Bil |
United States